Home > Press > BIDMC Scientists Receive Challenge Awards from Prostate Cancer Foundation
Beth Israel Deaconess Medical Center (BIDMC) researchers Martin Sanda, MD, and Steven Balk MD, PhD, have been awarded Challenge Awards of $1 million each from the Prostate Cancer Foundation (PCF) to lead two cross-disciplinary teams of investigators in their pursuit of new treatments for patients with advanced prostate cancer. The PCF Challenge Awards will support a total of 10 scientific projects nationwide; BIDMC is the only institution to receive funding for two projects.
BIDMC Scientists Receive Challenge Awards from Prostate Cancer Foundation
Boston, MA | Posted on August 9th, 2011
Said PCF executive vice president and chief science officer Howard Soule, PhD, "With reductions in federal funding for prostate cancer research, it's imperative for the PCF to seek the most promising research ideas and fund them with the goal of changing clinical practice and improving outcomes for patients with advanced prostate cancer."
The research team assembled by Sanda, Director of the Prostate Cancer Program at BIDMC and Associate Professor of Surgery/Urology at Harvard Medical School, is combining nanotechnology and cancer immunology expertise in developing a vaccine to treat prostate cancer by boosting patients' immune systems.
"Recent progress has shown that cancer vaccines extend survival for men with prostate cancer and this type of treatment has now been approved by the U.S. Food and Drug Administration," explains Sanda. "However, this first-generation prostate cancer vaccine is exceedingly expensive, and the cumbersome processing of individual patient cells limits availability. Our strategy, which makes use of biodegradable nanoparticles to directly deliver prostate-cancer proteins to the body's requisite immune cells, will stimulate the immune system to directly attack prostate-cancer cells and, therefore, has the potential to be less expensive and more easily disseminated."
Sanda's Prostate Cancer Nanoparticle Vaccine Consortium is co-led by M. Simo Arredouani, PhD, of BIDMC's Department of Surgery; Joseph DeSimone, PhD, of the University of North Carolina Department of Chemistry, and Charles Drake, MD, PhD, of the Johns Hopkins Sidney Kimmell Cancer Center.
"Our work represents a synergistic collaboration that brings together some of the best doctors and scientists in the fields of prostate cancer, nanotechnology, and cancer immunotherapy across three separate leading hospitals," adds Sanda. "Such collaborative team science is the cornerstone for continued progress in developing effective new cancer therapies."
In the second of BIDMC's PCF Challenge Awards, a scientific team led by Steven Balk, MD, PhD, an investigator in BIDMC's Division of Hematology/Oncology and Professor of Medicine at Harvard Medical School, will work on research to identify and exploit mechanisms of response and resistance to therapeutics directed at the androgen receptor pathway.
"We hope to learn why patients invariably become resistant to Abiraterone acetate, a treatment used in advanced prostate-cancer cases following chemotherapy," says Balk. "If we can determine the reasons why this treatment eventually stops working, we will be better equipped to design more effective and targeted therapy for metastatic treatment-resistant disease, the lethal stage of prostate cancer responsible for approximately 30,000 deaths per year."
Co-investigators on the Balk project include BIDMC researchers Glenn Bubley, MD, and Xin Yuan, MD; and Dana-Farber Cancer Institute investigators Toni Choueiri, MD, Phillip Kantoff, MD, Christopher Sweeney, MD and Mary-Ellen Taplin, MD. Co-principal investigators include Peter Nelson, MD, of the University of Washington/Fred Hutchinson Cancer Research Center and Trevor Penning, PhD, of the University of Pennsylvania.
About Beth Israel Deaconess Medical Center
Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School and is ranked third in National Institutes of Health funding among independent hospitals nationwide. BIDMC is a clinical partner of the Joslin Diabetes Center and a research partner of the Dana-Farber/Harvard Cancer Center. BIDMC is the official hospital of the Boston Red Sox.
For more information, please click here
Copyright © Newswise
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
News and information
East China University of Science and Technology Purchases Nanonex Advanced Nanoimprint Tool NX-B200 July 30th, 2014
Watching Schrödinger's cat die (or come to life): Steering quantum evolution & using probes to conduct continuous error correction in quantum computers July 30th, 2014
From Narrow to Broad July 30th, 2014
FLAG-ERA and TNT2014 join efforts: Graphene Networking at its higher level in Barcelona: Encourage the participation in a joint transnational call July 30th, 2014
New imaging agent provides better picture of the gut July 30th, 2014
Zenosense, Inc. July 29th, 2014
Optimum inertial design for self-propulsion: A new study investigates the effects of small but finite inertia on the propulsion of micro and nano-scale swimming machines July 29th, 2014
FEI adds Phase Plate Technology and Titan Halo TEM to its Structural Biology Product Portfolio: New solutions provide the high-quality imaging and contrast necessary to analyze the 3D structure of molecules and molecular complexes July 28th, 2014
University of Manchester selects Anasys AFM-IR for coatings and corrosion research July 30th, 2014
Nature inspires a greener way to make colorful plastics July 30th, 2014
Analytical solutions from Malvern Instruments support University of Wisconsin-Milwaukee researchers in understanding environmental effects of nanomaterials July 30th, 2014
FEI Unveils New Solutions for Faster Time-to-Analysis in Metals Research July 30th, 2014
New imaging agent provides better picture of the gut July 25th, 2014
Hysitron is Awarded TWO R&D 100 Awards for Highly Innovative Technology Developments in the Areas of Extreme Environments and Biological Mechanical Property Testing July 23rd, 2014
Researchers create vaccine for dust-mite allergies Main Page Content: Vaccine reduced lung inflammation to allergens in lab and animal tests July 22nd, 2014
EPFL Research on the use of AFM based nanoscale IR spectroscopy for the study of single amyloid molecules wins poster competition at Swiss Physics Society meeting July 22nd, 2014
New imaging agent provides better picture of the gut July 30th, 2014
Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster: University of Leicester research team unlocks insights into creation of new nano-materials July 25th, 2014
A*STAR and industry form S$200M semiconductor R&D July 25th, 2014
A Crystal Wedding in the Nanocosmos July 23rd, 2014